Paritaprevir
CAS: 1216941-48-8
Ref. 3D-AP178043
| 5mg | To inquire | ||
| 10mg | To inquire | ||
| 25mg | To inquire | ||
| 50mg | To inquire | ||
| 100mg | To inquire |
Product Information
- (2R,6S,12Z,13aS,14aR,16aS)-N-(Cyclopropylsulfonyl)-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-6-[[(5-methyl-2-pyrazinyl)carbonyl]amino]-5,16-dioxo-2-(6-phenanthridinyloxy)cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxamide
- Abt 450
- Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxamide, N-(cyclopropylsulfonyl)-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-6-[[(5-methyl-2-pyrazinyl)carbonyl]amino]-5,16-dioxo-2-(6-phenanthridinyloxy)-, (2R,6S,12Z,13aS,14aR,16aS)-
- ABT450
Paritaprevir is an inhibitor drug that is used in the treatment of hepatitis C. It binds to the active site of the viral polymerase and blocks viral RNA synthesis. Paritaprevir has a half-life of about 3 hours and a concentration-time curve that results in an interactive response with wild-type virus, which may lead to antiviral resistance. Paritaprevir has been shown to be effective for patients with hepatic impairment, but it is not recommended for patients who are obese or have a body mass index greater than 30 kg/m2 because these conditions can increase the risk of adverse effects.
Chemical properties
Technical inquiry about: 3D-AP178043 Paritaprevir
If you want to request a quotation or place an order, please instead add the desired products to your cart and then request a quotation or order from the cart. It is faster, cheaper, and you will be able to benefit from the available discounts and other advantages.
